MIRIPLATIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C14H27O2.C6H14N2.Pt
Molecular Weight	763.999
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Pt++].N[C@@H]1CCCC[C@H]1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O

InChI

InChIKey=BGIHRZPJIYJKAZ-BLUNCNMSSA-L

InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1

HIDE SMILES / InChI

Molecular Formula	Pt
Molecular Weight	195.084
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C14H27O2
Molecular Weight	227.363
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C6H14N2
Molecular Weight	114.1888
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.sumitomo-chem.co.jp/english/rd/report/theses/docs/2011-1E_04.pdf | http://www.ds-pharma.com/ir/news/pdf/ene20091215.pdf

Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Miriplatin hydrate was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Oct 16, 2009. It was developed and marketed as Miripla® by Dainippon Sumitomo Pharma on Jan 20, 2010 in Japan. Miriplatin hydrate is a lipophilic platinum complex that has high affinity to lipiodol. It is indicated for the treatment of transcatheter arterial chemoembolization of hepatocellular carcinoma. Miripla® is available as lyophilized powder for arterial injection, containing 70 mg of free Miriplatin. The recommended dose is 70 mg once daily.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10744050 \| http://adisinsight.springer.com/drugs/800003094	Crosslinking Agent 81

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hepatocellular carcinoma 83 Sources: http://www.ds-pharma.com/ir/news/pdf/ene20091016.pdf http://adisinsight.springer.com/drugs/800003094	Primary		Approved 8429	MIRIPLA Approved Use Lipiodolization in hepatocellular carcinoma Launch Date 1.25565115E12

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

70 mg of miriplatin is suspended in 3.5 mL of suspension vehicle for this drug, and administered once a day through catheter inserted into hepatic artery. Administration of miriplatin-suspension ends when tumor vessel is filled with the drug, provided that the upper limit should be 6 mL per administration (equivalent to 120 mg of miriplatin). An observation period of 4 weeks or longer is required in the case of repeated administration.

Route of Administration: Intra-arterial

In Vitro Use Guide

Miriplatin (SM-11355) suspended in Lipiodol (SM-11355/Lipiodol) showed cytotoxic activity against rat ascites hepatoma AH-109A cells in a dose-dependent manner. IC50 value following 7-day exposure was 22.3 ug/ml.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:33:17 UTC 2023` Edited by `admin` on `Sat Dec 16 01:33:17 UTC 2023`
Record UNII	780F0P8N4I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MIRIPLATIN

Official Name

English

SM-11355

Code

English

MIRIPLA

Brand Name

English

Miriplatin [WHO-DD]

Common Name

English

MIRIPLATIN [MI]

Common Name

English

CYCLOHEXANE-(1R,2R)-DIAMINEPLATINUM(II) DIMYRISTATE

Common Name

English

miriplatin [INN]

Common Name

English

Code System Code Type Description

EVMPD

SUB34987